Navigation Links
Catalyst Biosciences Appoints Dr. Todd Lorenz Chief Medical Officer
Date:10/28/2008

SOUTH SAN FRANCISCO, Calif., Oct. 28 /PRNewswire/ -- Catalyst Biosciences, Inc., a pioneer in the discovery and development of engineered proteases known as Alterase(TM) therapeutics, has appointed Todd Lorenz, M.D., as the company's Chief Medical Officer. Dr. Lorenz's career encompasses nearly 20 years of experience focused on the clinical development of novel medicines.

"We are excited to welcome Dr. Lorenz to the Catalyst team," said Nassim Usman, Ph.D., Chief Executive Officer of Catalyst Biosciences. "Hiring an experienced CMO to lead our development efforts is a critical step as Catalyst expands from drug discovery into clinical development. His expertise in clinical development and operations is particularly welcome as we advance our lead program, CB 813, an improved factor VIIa product for the treatment of acute bleeding in hemophiliacs, toward an IND filing in 2009."

"I am delighted to join Catalyst and have the opportunity to shape the clinical strategy for the company's pipeline of protease therapeutics," said Dr. Lorenz. "CB 813 is a highly promising compound with the potential to become a best-in-class therapeutic for hemophilia patients. Catalyst's protease therapeutics platform is poised to deliver a new class of biologics comparable in depth and scope to monoclonal antibodies."

Throughout his career, Dr. Lorenz has held leadership positions in the biotechnology and pharmaceutical industry with responsibilities across several therapeutic areas. Dr. Lorenz joins Catalyst from Johnson & Johnson (J&J), where he was Vice President and Associate Therapeutic Head for Cardiovascular Development. In this role, he contributed to clinical development efforts in several internal J&J entities including Scios, the Corporate Office of Science and Technology and Peninsula Pharmaceuticals. Dr. Lorenz served as Chief Medical Officer for Orexigen Therapeutics from 2005-2006 and was Chief Medical Officer at Corgentech from 2001-2005 where he was responsible for the clinical development of a transcription factor inhibitor through Phase 3 clinical development. From 1994-2001 at COR Therapeutics, Dr. Lorenz was intimately involved in the development, approval and medical affairs support for Integrilin(R), a novel platelet inhibitor, and from 1990-1994 he focused on the development of immunology product candidates at XOMA.

Dr. Lorenz is a graduate of Case Western Reserve University School of Medicine and trained in Internal Medicine at the University of Texas Southwestern. He completed a fellowship in Endocrinology and Metabolism at the University of California, San Francisco, and is board certified in both subspecialties. Dr. Lorenz has published extensively in journals such as Journal of the American Medical Association (JAMA), The Lancet, Circulation and the Annals of Thoracic Surgery.

About Catalyst Biosciences

Catalyst Biosciences is developing the next generation of biopharmaceuticals by harnessing the catalytic power of engineered proteases to target proteins underlying disease. Catalyst's discovery platform rapidly creates and optimizes tailor-made protease drug candidates that cleave a wide variety of disease targets, either by improving existing protease drugs or by creating new protease drugs, known as Alterase(TM) therapeutics. Initially, Catalyst is focusing its product development efforts on drug candidates for hemophilia, age-related macular degeneration, oncology and inflammation. To date, Catalyst has established two discovery research and product development agreements with Wyeth Pharmaceuticals and Centocor Research & Development, Inc. Catalyst is privately-held with backing by leading venture firms including Burrill & Company, HealthCare Ventures, Johnson & Johnson Development Corporation, Morgenthaler Ventures, Novartis BioVentures, RCT BioVentures and Sofinnova Ventures. For more information, please visit http://www.catbio.com.

Catalyst Biosciences, Inc.

Erik Wiberg

Chief Financial Officer

+1.650.266.8654

ewiberg@catbio.com

BCC Partners for Catalyst Biosciences, Inc.

Karen L. Bergman or Michelle Corral

+1.650.575.1509 or +1.415.794.8662


'/>"/>
SOURCE Catalyst Biosciences, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
2. Cardiva Medical, Inc. to Present at the UBS 2007 Global Life Science Conference With the Announcement of FDA 510(K) Clearance of its Newest Device: The Boomerang Catalyst II System(TM)
3. Catalyst Pharmaceutical Partners Reports Third Quarter 2007 Financial Results
4. Catalyst Pharmaceutical Partners Announces Positive Phase II Trial Results for Vigabatrin in the Treatment of Cocaine Addiction
5. CATalyst Summit Declared a Success: Its All About the Cat!
6. Cardiva Medical, Inc. to Present Highlights of the Boomerang Catalyst(TM) II System at the Investment in Innovation (In3) West Conference on February 29, 2008 in Las Vegas, NV
7. Catalyst Pharmaceutical Partners, Inc. Names Director - Corporate Clinical Compliance
8. Case in Point: Patient Control of Data Critical Catalyst for Online Health Care Revolution
9. Catalyst Pharmaceutical Partners, Inc. Set to Join Russell Microcap(R) Index
10. Congress Approves ePrescribing Initiative in Medicare Reform Bill: Critical Catalyst in Driving a New Generation of Prescribing
11. CATalyst Council Forms to Address Feline Health Care
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2016)... ... December 04, 2016 , ... Patients ... can now take advantage of a cosmetic procedure known as Carbon Dioxide ... reduces the appearance of age spots, fine lines, uneven coloration, wrinkles, scarring, ...
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in ... Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New ... Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and ...
(Date:12/2/2016)... AL (PRWEB) , ... December 02, 2016 , ... ... from across the Dothan-Wiregrass Area in Alabama are expected to attend the UNCF ... Schmitz, will help provide scholarship funds for area students and operating support to ...
(Date:12/2/2016)... ... ... The annual time frame to change Medicare health and prescription drug coverage, ... Currently-enrolled Medicare beneficiaries who are looking to switch from their current plan to a ... changes during this period order for their new policy to go into effect in ...
(Date:12/2/2016)... ... 02, 2016 , ... Dr. Raffi Hovsepian, a leading plastic, ... 2016 “Guide to America’s Top Plastic Surgeons” for seven consecutive years. The prestigious ... experience, and professional associations. , One the most frequently honored surgeons in ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... -- A highly innovative, personalized cell-based treatment for a high-risk form of ... oncologists from Children,s Hospital of Philadelphia today reported ... leukemia (ALL). The physician-scientists presented findings at the annual meeting ... . Continue Reading ... ...
(Date:12/2/2016)... Columbia , December 2, 2016 bioLytical Laboratories, un ... la Compañía, el INSTI HIV Self Test , a los miembros de ... ... INSTI HIV Self Test! (PRNewsFoto/bioLytical Laboratories) ...      (Photo: http://photos.prnewswire.com/prnh/20161201/444905 ) ...
(Date:12/2/2016)... DUBLIN , Dec 2, 2016 Research ... Market Size, Share, Development, Growth and Demand Forecast to 2022" report ... , , ... revenue of $6 billion in 2015, and it is expected to grow ... ultrasound segment is expected to witness faster growth during the forecast period, ...
Breaking Medicine Technology: